Trial Profile
Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma
Status:
Discontinued
Phase of Trial:
Phase 0
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary) ; Melphalan
- Indications Multiple myeloma
- Focus Adverse reactions
- 05 Feb 2020 Status changed from recruiting to discontinued.
- 12 Apr 2019 Planned End Date changed from 27 Nov 2019 to 1 May 2020.
- 12 Apr 2019 Planned primary completion date changed from 27 Nov 2018 to 1 May 2020.